ARTICLE
14 August 2024

Pharmacy Industry Groups Ask Supreme Court To Overturn OK PBM Ruling

HB
Hall Benefits Law

Contributor

Strategically designed, legally compliant benefit plans are the cornerstone of long-term business stability and growth. As such, HBL provides comprehensive legal guidance on benefits in M&A, ESOPs, executive compensation, health and welfare benefits, retirement plans, and ERISA litigation matters. Responsive, relationship-driven counsel is the calling card of the Firm.
Five pharmacy industry groups have filed an amicus brief supporting the Oklahoma insurance commissioner's petition for a writ of certiorari to the U.S. Supreme Court concerning a recent Tenth Circuit decision.
United States Oklahoma Employment and HR
To print this article, all you need is to be registered or login on Mondaq.com.

Five pharmacy industry groups have filed an amicus brief supporting the Oklahoma insurance commissioner's petition for a writ of certiorari to the U.S. Supreme Court concerning a recent Tenth Circuit decision. That ruling partially invalidated a state law regulating pharmacy benefit managers (PBMs). The case is Glen Mulready et al. v. Pharmaceutical Care Management Association, case number 23-1213, U.S. Supreme Court.

In the Tenth Circuit decision, a unanimous three-judge panel found that the Employment Retirement Income Security Act (ERISA) and Medicare Part D preempted Oklahoma's Patients' Right to Pharmacy Choice Act. The state law limits the ability of health insurance plans and their PBMs to choose which pharmacies and cost-sharing amounts plan beneficiaries can use for their prescription drug benefits.

According to the pharmacy industry groups, PBMs, which function as intermediaries between pharmacies, health insurance companies, and drugmakers, fail to drive down patient costs and abuse their market power to benefit only themselves. They claim that the three major PBMs – Express Scripts, CVS Caremark, and Optum Rx – have consolidated most of the market power and wealth, driven small pharmacies out of business, and increased medication costs. The pharmacy industry groups suggest that PBMs have inflicted the worst damage in rural America, such as in many parts of Oklahoma, thus leading to this law's passage.

The pharmacy industry groups further argued in their amicus brief that if the Tenth Circuit ruling remains in place, no regulation of PBMs will be possible. As a result, PBMs will continue to harm pharmacists and patients, even though the statute does not interfere with ERISA's regulatory scheme.

Many other states have laws like Oklahoma's regulating PBMs for the same reasons. Based on the Tenth Circuit's decision, these states are rethinking their laws.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More